Katharina Busl

Professor/Chief University of Florida

  • Gainesville FL

Dr. Katharina Busl is an expert in subarachnoid hemorrhages, acute brain injuries, acute spine injuries and neurocritical care.

Contact

University of Florida

View more experts managed by University of Florida

View all Experts

Biography

Dr. Katharina Busl is the chief of the Division of Neurocritical Care, professor, and associate chair of clinical operations in the Department of Neurology. She is an internationally recognized expert in neurocritical care. She has co-authored clinical guidelines for the management of subarachnoid hemorrhage, neuroprognostication guidelines for neurocritical diseases and numerous manuscripts relevant to clinical neurocritical care. Clinical interests include subarachnoid hemorrhage, neuroprognostication, her research interests center around care innovations and quality of care in neurocritical care. Specific interests include treatment of headaches in the NeuroICU, neuroprognostication and medical complications of neurocritical disease. Dr. Busl is the lead PI for BLOCK-SAH, an NIH-funded, multicenter trial to investigate pterygopalatine fossa nerve blocks for post-subarachnoid hemorrhage headaches.

Areas of Expertise

Critical Care Neurology
Acute Brain Injury
Subarachnoid Hemorrhage

Social

Articles

Role of Dexmedetomidine in Aneurysmal Subarachnoid Hemorrhage: A Comprehensive Scoping Review

Journal of Neurosurgical Anesthesiology

Katharina M. Busl, et al.

2022-04-01

Dexmedetomidine has been widely used for anesthesia, pain control, and intensive care unit sedation. Subarachnoid hemorrhage is a complex disease that is divided into 2 phases: early brain injury and delayed cerebral ischemia. Dexmedetomidine has been shown to have an effect on these Subarachnoid hemorrhage-related pathologic processes.

View more

Pregabalin for Recurrent Seizures in Critical Illness: A Promising Adjunctive Therapy, Especially for cyclic Seizures

Neurocritical Care

Katharina M. Busl, et al.

2022-02-25

Pregabalin is an effective adjunctive treatment for focal epilepsy and acts by binding to the alpha2-delta subunit of voltage-gated calcium channels to reduce excitatory neurotransmitter release. Pregabalin has been shown to increase spreading depolarization threshold; hence, we hypothesized that the magnitude of antiseizure effect from pregabalin is more pronounced in patients with cyclic versus noncyclic seizures in a critically ill cohort with recurrent seizures.

View more

Early vigabatrin augmenting GABA-ergic pathways in post-anoxic status epilepticus (VIGAB-STAT) phase IIa clinical trial study protocol

Neurological Research and Practice

Katharina M. Busl, et al.

2022-01-24

Nearly one in three unconscious cardiac arrest survivors experience post-anoxic status epilepticus. Historically, post-anoxic status epilepticus has been deemed untreatable resulting in its exclusion from status epilepticus clinical trials. However, emerging reports of survivors achieving functional independence following early and aggressive treatment of post-anoxic status epilepticus challenged this widespread therapeutic nihilism.

View more

Media

Powered by